Xilio Therapeutics (XLO) Institutional Ownership $0.71 0.00 (-0.34%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$0.73 +0.02 (+3.09%) As of 08:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Xilio Therapeutics (NASDAQ:XLO)CurrentInstitutional OwnershipPercentage54.29%Number ofInstitutional Buyers(last 12 months)10TotalInstitutional Inflows(last 12 months)$10.82MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$1.91M Get XLO Insider Trade Alerts Want to know when executives and insiders are buying or selling Xilio Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data XLO Institutional Buying and Selling by Quarter Remove Ads Xilio Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/17/2025Trustees of Columbia University in the City of New York249,635$238K0.0%N/A0.568% 2/17/2025Balyasny Asset Management L.P.343,230$328K0.0%+26.0%0.781% 2/17/2025Aptus Capital Advisors LLC41,000$39K0.0%N/A0.093% 2/14/2025Gilead Sciences Inc.9,105,451$8.70M0.6%N/A20.713% 2/13/2025Raymond James Financial Inc.50,086$48K0.0%N/A0.114% 2/13/2025Renaissance Technologies LLC296,617$283K0.0%+11.4%0.675% 2/12/2025Geode Capital Management LLC358,422$342K0.0%+6.0%0.815% 2/12/2025Takeda Pharmaceutical Co. Ltd.1,475,121$1.42M5.3%N/A3.356% 2/6/2025Raymond James Financial Inc.50,086$48K0.0%N/A0.114% 11/16/2024Geode Capital Management LLC338,192$266K0.0%+85.0%0.769% Get the Latest News and Ratings for XLO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/12/2024XTX Topco Ltd33,289$32K0.0%N/A0.076% 8/9/2024Renaissance Technologies LLC295,000$280K0.0%+18.3%0.799% 5/6/2024Atlas Venture Life Science Advisors LLC992,912$1.07M0.1%-64.0%2.690% 4/22/2024PFG Investments LLC30,000$32K0.0%N/A0.087% 2/15/2024Octagon Capital Advisors LP1,785,000$982K0.2%-23.0%6.481% 11/14/2022Ergoteles LLC12,941$38K0.0%-26.3%0.047% 8/15/2022Laurion Capital Management LP142,900$417K0.0%N/A0.520% 7/27/2022Bailard Inc.36,632$107K0.0%N/A0.133% 5/16/2022Deerfield Management Company L.P. Series C2,078,692$14.70M0.3%-3.5%7.567% 5/12/2022Monashee Investment Management LLC163,066$1.15M0.3%-23.9%0.594% 2/15/2022Davidson Kempner Capital Management LP29,000$458K0.0%N/A0.109% 2/14/2022Deerfield Management Company L.P. Series C2,154,061$33.74M0.7%N/A8.078% 2/14/2022Ghisallo Capital Management LLC30,000$480K0.0%N/A0.113% 2/14/2022Soleus Capital Management L.P.477,495$7.64M0.8%N/A1.791% 2/11/2022Granite Point Capital Management L.P.10,000$160K0.0%N/A0.038% 2/9/2022 AJU IB Investment Co. Ltd.667,742$10.68M14.9%N/A2.504% 2/8/2022Northern Trust Corp63,034$1.01M0.0%N/A0.236% 2/7/2022Monashee Investment Management LLC214,253$3.43M0.8%N/A0.803% 2/7/2022RiverVest Venture Management LLC1,441,444$23.06M16.5%N/A5.406% 2/2/2022New York State Common Retirement Fund5,568$89K0.0%N/A0.021% (Data available from 1/1/2016 forward)Remove Ads XLO Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of XLO shares? During the previous two years, 12 institutional investors and hedge funds held shares of Xilio Therapeutics. The most heavily invested institutionals were Gilead Sciences Inc. ($8.70M), Takeda Pharmaceutical Co. Ltd. ($1.42M), Atlas Venture Life Science Advisors LLC ($1.07M), Octagon Capital Advisors LP ($982K), Geode Capital Management LLC ($342K), Balyasny Asset Management L.P. ($328K), and Renaissance Technologies LLC ($283K).Learn more on XLO's institutional investors. What percentage of Xilio Therapeutics stock is owned by institutional investors? 54.29% of Xilio Therapeutics stock is owned by institutional investors. Learn more on XLO's institutional investor holdings. Which institutional investors have been buying Xilio Therapeutics stock? Of the 10 institutional investors that purchased Xilio Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Gilead Sciences Inc. ($9.11M), Takeda Pharmaceutical Co. Ltd. ($1.48M), Trustees of Columbia University in the City of New York ($249.64K), Geode Capital Management LLC ($175.57K), Raymond James Financial Inc. ($100.17K), Renaissance Technologies LLC ($75.87K), and Balyasny Asset Management L.P. ($70.74K). How much institutional buying is happening at Xilio Therapeutics? Institutional investors have bought a total of 11,356,850 shares in the last 24 months. This purchase volume represents approximately $10.82M in transactions. Which Xilio Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Xilio Therapeutics stock in the last 24 months: Atlas Venture Life Science Advisors LLC ($1.77M), and Octagon Capital Advisors LP ($533.50K). How much institutional selling is happening at Xilio Therapeutics? Institutional investors have sold a total of 2,299,932 shares in the last 24 months. This volume of shares sold represents approximately $2.20M in transactions. Related Companies CTNM Institutional Ownership RAPT Institutional Ownership TNGX Institutional Ownership TARA Institutional Ownership ACTU Institutional Ownership LYEL Institutional Ownership GLSI Institutional Ownership IKT Institutional Ownership PRQR Institutional Ownership FDMT Institutional Ownership This page (NASDAQ:XLO) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.